Method for detecting anti-tuberculosis drug in serum by ultra-high performance liquid chromatography-tandem mass spectrometry technology

Abstract

The invention discloses a method for detecting an anti-tuberculosis drug in serum by an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The antitubercular drug comprises cycloserine (CYS), pyrazinamide (PZN), isoniazid (INZ), p-aminosalicylic acid (P-ASA), ethiisonicotinamide (ETN), ethambutol (ETB), clofazimine (CFM), bedaquiline (BDQ), rifampicin (RFP), rifbutine (RFB) and rifapentine (RFT). The method includes: detecting the content of the antituberculosis drug in the pretreated serum by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry method, performing quantifying by utilizing a mass spectrometry isotope internal standard method, establishing a calibration curve by taking the concentration ratio of the standard substance to the internal standard substance as an X axis and the peak area ratio of the standard substance to the internal standard substance as a Y axis, and calculating the concentration of the target drug in the serum; the method is high in sensitivity, strong in specificity and simple in pretreatment process, separation and detection of the anti-tuberculosis drugs in serum are completed within 5 min, and a simple and rapid detection method is provided for clinical concentration monitoring of the anti-tuberculosis drugs.

Description

technical field [0001] The invention belongs to the technical field of analysis and detection, and more specifically relates to a method for detecting anti-tuberculosis drugs in serum by ultra-high performance liquid chromatography tandem mass spectrometry. Background technique [0002] Tuberculosis is an infectious disease caused by patients infected with Mycobacterium tuberculosis. So far, tuberculosis is still the infectious disease that causes the highest human mortality rate except AIDS. Anti-tuberculosis drugs are mainly divided into four categories: first-line anti-tuberculosis drugs, second-line anti-tuberculosis drugs, new anti-tuberculosis drugs, and compound drugs. [0003] In this patent, the first-line anti-tuberculosis drugs involved mainly include rifampicin (Rifamicin, RMP), isoniazid (Isoniazid, INH), pyrazinamide (Pvrazinamide, PZA) and ethambutol (Ethambutol, EMB) ; First-line anti-tuberculosis drugs are still the first choice for the treatment of tubercu...

AI Technical Summary

Problems solved by technology

It is easy to cause the drug concentration in the body to be too low, so that the therapeutic drug concentration cannot be reached, or the drug concentration in the body is too high to cause toxic reactions. sex is more important

[0004] At present, the method for detecting the concentration of anti-tuberculosis drugs in the body is mainly ultra-high performance liquid chromatography-tandem mass spectrometry. Most of the reports in the literature are for the detection of 1-3 kinds of drugs at one time, and there are also patent reports for the detection of 5 kinds of anti-tuberculosis drugs, such as Chinese patent application (publication number: CN 110146620 A) discloses a "method for simultaneous detection of five anti-tuberculosis drugs in plasma by UPLC-MS / MS method". Gao; Chinese patent application (publication number: CN 109682915 A) discloses a "method for the determination of pyrazinamide concentration in plasma by liquid chromatography-mass spectrometry". There are many types and the detection process is cumbersome

Images